Clinical trials: Single Dose
Diabetes Mellitus, Non-Insulin-Dependent, Dyslipidemia
Safety Study of BMS-816336 in Healthy Male Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.
- Trial name
- NCT00979368
- Testing
- BMS-816336
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
COVID-19; and High Infection Risk of SARS-CoV-2
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese…
- Trial name
- NCT04441918
- Testing
- JS016 (anti-SARS-CoV-2 monoclonal antibody)
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Pulmonary Embolism, Right Ventricular Dysfunction
Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE
SONIC-PE is a multicenter, prospective, single-arm study of 10 patients with bilateral PE treated with ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (total dose 8 mg tPA given as 2 mg/hour/catheter over 2…
- Conditions
- Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
- Trial name
- SONIC-PE (NCT06310018)
- Testing
- Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Healthy
Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection
VVZ-149 is a novel analgesic drug candidate that shows a potential analgesic activity inhibiting GlyT2 and 5HT2A simultaneously.
- Trial name
- P1_VVZ149IV (NCT01905410)
- Testing
- VVZ-149 Injection
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vivozon, Inc.
Healthy Volunteers
A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men
The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of [14C]-OPC-167832 in healthy male participants.
- Trial name
- NCT07314320
- Testing
- [14C]-OPC-167832
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Elevated LDL-Cholesterol (LDL-C)
Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-PCS02 in subjects with Elevated LDL-Cholesterol (LDL-C).
- Trial name
- NCT01437059
- Testing
- ALN-PCS02, Sterile Normal Saline (0.9% NaCl)
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone.
- Trial name
- NCT01363479
- Testing
- Oral palonosetron, I.V. palonosetron, Dexamethasone
- Where
- 79 sites in United States, Argentina and 10 more
- Volunteers
- 743 people
- Sponsor
- Helsinn Healthcare SA
Hyperlipemia
A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022
This is a randomized, single blind, placebo controlled, single center phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously…
- Trial name
- NCT05912296
- Testing
- RBD7022
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Suzhou Ribo Life Science Co. Ltd.
Pharmacokinetics
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a novel liquid formulation for the…
- Trial name
- NCT02957396
- Testing
- Finerenone (BAY94-8862): 20 mg intact tablet, Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet, Finerenone (BAY94-8862): 20 mg suspension
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06266047 after first-time administration to healthy adult subjects.
- Trial name
- NCT02539550
- Testing
- PF-06266047
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acute Myeloid Leukemia
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
Erwinaze will be administered intravenously at a dose of 25,000 IU/m2 (dose cohort 0) for 6 doses MWF over a period of 2 weeks to 9 patients (as described below and in the following schema).
- Trial name
- NCT02283190
- Testing
- Erwinase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ashkan Emadi
Healthy
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal…
- Trial name
- NCT01888497
- Testing
- Gabapentin, Diphenhydramine citrate, Triazolam
- Where
- 4 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain
A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects
The objective of the study is to compare the bioequivalence of a New Paracetamol Oral Suspension 24 milligram/milliliter (mg/ml) with that of an already approved Paracetamol (24 mg/ml) Oral Suspension (Panadol Baby \& Infant)…
- Trial name
- NCT05022810
- Testing
- New Paracetamol Oral Suspension (24 mg/ml), Panadol B&I Oral Suspension (24 mg/ml paracetamol)
- Where
- Czechia
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- HALEON
Healthy
A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled (with and without charcoal) via Respimat.
- Trial name
- NCT03907280
- Testing
- BI 1265162 (T1), BI 1265162 (T2), BI 1265162 (R)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Clinical Study of BG136 Injection in Healthy Chinese Volunteers
This is a first-in-human, randomized, double-blind, placebo-controlled trial in healthy subjects. The trial consisted of two parts: part 1: single ascending dose (SAD) study and part 2: multiple ascending dose (MAD) study.
- Trial name
- NCT05984368
- Testing
- BG136
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
High-risk Prostate Cancer
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients
Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional…
- Trial name
- CHIRP (NCT01488968)
- Testing
- Standard Radiation Treatment, Hypofractionated radiation treatment
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- AHS Cancer Control Alberta
Hemophilia B
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile. The study drug is identified as AAV5-hFIXco-Padua (AMT- 061).
- Trial name
- NCT03569891
- Testing
- AAV5-hFIXco-Padua, Factor IX (FIX)
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 67 people
- Sponsor
- CSL Behring
Healthy
Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers
To investigate the effects on airway lumen of talsaclidine in combination with propranolol and of talsaclidine and propranolol given as monosubstances
- Trial name
- NCT02264093
- Testing
- Propranolol, Talsaclidine
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infection, Infection, Human Immunodeficiency Virus
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body.
- Trial name
- NCT00386347
- Testing
- GSK364735 oral solution and oral tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.